Liabooks Home|PRISM News
The Hong Kong Stock Exchange building with digital data overlays
EconomyAI Analysis

Mainland TCM Firms Eye Global Expansion via Hong Kong IPOs in 2026

2 min readSource

TCM giants like Sichuan Neautus and Herb Standard are pursuing Hong Kong IPOs to fuel global expansion in 2026. Explore the intersection of ancient medicine and global finance.

Ancient remedies are chasing modern capital. Traditional Chinese Medicine (TCM) manufacturers are queuing up for Hong Kong IPOs, signaling a massive push into the global healthcare market. Sichuan Neautus Traditional Chinese Medicine and Herb Standard are leading the charge, testing international investors' appetite for a sector long considered a niche.

Sichuan Neautus: A Bridge Between Tradition and Foreign Capital

During a forum hosted by InvestHK on Thursday, Jiang Feng, General Manager of Sichuan Neautus, highlighted Hong Kong's role as a vital hub for capital, R&D, and international settlement. The firm, which applied for its listing in October, is currently awaiting hearing approval.

What's striking is the company's international reach. Neautus already operates in 10 overseas markets, including the US, Germany, and South Korea. Furthermore, foreign capital already accounts for 30% of the funds raised from its existing investors, demonstrating strong global interest.

High-Tech Tradition: Herb Standard's AI Bet

Hong Kong-based Herb Standard is taking a more tech-centric approach. Its prospectus reveals plans to utilize IPO proceeds for expanding overseas production and developing Artificial Intelligence applications in manufacturing. They're part of a larger trend: 34 innovation and tech firms have expanded operations in Hong Kong over the past year.

This content is AI-generated based on source articles. While we strive for accuracy, errors may occur. We recommend verifying with the original source.

Related Articles